Lonza Introduces Applied Protein Services Preclinical Platform to Improve Biologic Development Success

June 10,2010 Basel, Switzerland

Lonza, a leader in biopharmaceutical development services and contract manufacturing, is launching a new set of immunogenicity, stability and protein engineering services to benefit customers. The newly integrated Applied Protein Services platform is effective at improving the quality, safety, efficacy and manufacturability of antibodies, therapeutic proteins and vaccines.

“Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical program,” said Philippe Stas, Head of Lonza’s Applied Protein Services group. “Our newly integrated preclinical services help mitigate both aspects by providing a window into the future of a biologic, which supports the successful selection and optimization as well as the early process development of promising drug candidates.”

The Applied Protein Services platform complements Lonza’s well-established, industry-leading process development and manufacturing capabilities while advancing the company’s efforts to incorporate Quality by Design (QbD) principles.

 

Customer Services Available

Epibase™ & Epibase IV™

Computer-based and cellular immunoprofiling for lead selection, lead comparison, optimization and surveillance

 

Tripole™

Technology platform for protein structure analysis, modeling, engineering, deimmunization and antibody optimization

 

AggreSolve™

Technology platform to resolve protein aggregation and stability challenges

For more information, please contact one of Lonza’s Applied Protein Services experts at appliedproteinservices@lonza.com

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.

 

For further Information

Lonza Group Ltd
Head Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624
michael.frizberg@lonza.com

Lonza Group Ltd
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Browse All News
Bg